Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  HIV Infection

  Free Subscription

Articles published in Lancet Infect Dis

Retrieve available abstracts of 70 articles:
HTML format

Single Articles

    May 2022
  1. MOYO S, Ismail F, Van der Walt M, Ismail N, et al
    Prevalence of bacteriologically confirmed pulmonary tuberculosis in South Africa, 2017-19: a multistage, cluster-based, cross-sectional survey.
    Lancet Infect Dis. 2022 May 17. pii: S1473-3099(22)00149.
    PubMed     Abstract available

  2. LO NC, Bezerra FSM, Colley DG, Fleming FM, et al
    Review of 2022 WHO guidelines on the control and elimination of schistosomiasis.
    Lancet Infect Dis. 2022 May 17. pii: S1473-3099(22)00221.
    PubMed     Abstract available

  3. KELLY JD, Van Ryn C, Badio M, Fayiah T, et al
    Clinical sequelae among individuals with pauci-symptomatic or asymptomatic Ebola virus infection and unrecognised Ebola virus disease in Liberia: a longitudinal cohort study.
    Lancet Infect Dis. 2022 May 16. pii: S1473-3099(22)00127.
    PubMed     Abstract available

  4. NDJEKA N, Campbell JR, Meintjes G, Maartens G, et al
    Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study.
    Lancet Infect Dis. 2022 May 2. pii: S1473-3099(21)00811.
    PubMed     Abstract available

    April 2022
  5. STEED D, Collins J, Farris AB, Guarner J, et al
    Haemophagocytic lymphohistiocytosis associated with bartonella peliosis hepatis following kidney transplantation in a patient with HIV.
    Lancet Infect Dis. 2022 Apr 29. pii: S1473-3099(22)00276.
    PubMed     Abstract available

  6. YAN X, Jia Z, Zhang B
    Evaluating the risk compensation of HIV/AIDS prevention measures.
    Lancet Infect Dis. 2022;22:447-448.

    March 2022
  7. COHEN C, Kleynhans J, von Gottberg A, McMorrow ML, et al
    SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020-21.
    Lancet Infect Dis. 2022 Mar 14. pii: S1473-3099(22)00069.
    PubMed     Abstract available

  8. WELKER J, Pulido JD, Catanzaro AT, Malvestutto CD, et al
    Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study.
    Lancet Infect Dis. 2022 Mar 11. pii: S1473-3099(22)00058.
    PubMed     Abstract available

  9. NTOUMI F, Nachega JB, Aklillu E, Chakaya J, et al
    World Tuberculosis Day 2022: aligning COVID-19 and tuberculosis innovations to save lives and to end tuberculosis.
    Lancet Infect Dis. 2022 Mar 3. pii: S1473-3099(22)00142.

  10. MUSHTAQ A, Kazi F
    Updates in pre-exposure prophylaxis for HIV.
    Lancet Infect Dis. 2022;22:320.

    Mother-to-child transmission of HIV in Botswana.
    Lancet Infect Dis. 2022;22:319.

    February 2022
  12. NAIDOO K, Dookie N
    Can the GeneXpert MTB/XDR deliver on the promise of expanded, near-patient tuberculosis drug-susceptibility testing?
    Lancet Infect Dis. 2022 Feb 25. pii: S1473-3099(21)00613.
    PubMed     Abstract available

  13. DECROO T, van Deun A
    Implications of bedaquiline-resistant tuberculosis.
    Lancet Infect Dis. 2022;22:166-167.

    January 2022
  14. LANGE C, Bottger EC, Cambau E, Griffith DE, et al
    Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases.
    Lancet Infect Dis. 2022 Jan 25. pii: S1473-3099(21)00586.
    PubMed     Abstract available

  15. SRIDHAR S, Joaquin A, Bonaparte MI, Bueso A, et al
    Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
    Lancet Infect Dis. 2022 Jan 25. pii: S1473-3099(21)00764.
    PubMed     Abstract available

  16. DE VRIES HJC, de Laat M, Jongen VW, Heijman T, et al
    Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial.
    Lancet Infect Dis. 2022 Jan 19. pii: S1473-3099(21)00625.
    PubMed     Abstract available

  17. KIRBY T
    Long-acting injectable for HIV approved for use in the UK.
    Lancet Infect Dis. 2022;22:26.

    December 2021

  18. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial.
    Lancet Infect Dis. 2021 Dec 23. pii: S1473-3099(21)00751.
    PubMed     Abstract available

    Minoo Mohraz-Iran's leader in HIV research.
    Lancet Infect Dis. 2021;21:1640.

  20. KIRBY T
    Philippa Musoke-stop mother-to-child HIV transmission.
    Lancet Infect Dis. 2021;21:1641.

    November 2021
  21. DAWSON Q
    Is violence the only option to obtain health for HIV prisoners?
    Lancet Infect Dis. 2021 Nov 30. pii: S1473-3099(21)00757.

  22. DHANA A, Hamada Y, Kengne AP, Kerkhoff AD, et al
    Tuberculosis screening among ambulatory people living with HIV: a systematic review and individual participant data meta-analysis.
    Lancet Infect Dis. 2021 Nov 17. pii: S1473-3099(21)00387.
    PubMed     Abstract available

  23. ISMAIL NA, Omar SV, Moultrie H, Bhyat Z, et al
    Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study.
    Lancet Infect Dis. 2021 Nov 12. pii: S1473-3099(21)00470.
    PubMed     Abstract available

  24. GOLDSTONE SE, Giuliano AR, Palefsky JM, Lazcano-Ponce E, et al
    Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.
    Lancet Infect Dis. 2021 Nov 12. pii: S1473-3099(21)00327.
    PubMed     Abstract available

    October 2021
  25. KRUTIKOV M, Faust L, Nikolayevskyy V, Hamada Y, et al
    The diagnostic performance of novel skin-based in-vivo tests for tuberculosis infection compared with purified protein derivative tuberculin skin tests and blood-based in vitro interferon-gamma release assays: a systematic review and meta-analysis.
    Lancet Infect Dis. 2021 Oct 1. pii: S1473-3099(21)00261.
    PubMed     Abstract available

    September 2021
  26. RULE R, Mitton B, Govender NP, Hoffmann D, et al
    Spinal epidural abscess caused by Aspergillus spp masquerading as spinal tuberculosis in a person with HIV.
    Lancet Infect Dis. 2021 Sep 29. pii: S1473-3099(20)30979.
    PubMed     Abstract available

  27. Global, regional, and national sex differences in the global burden of tuberculosis by HIV status, 1990-2019: results from the Global Burden of Disease Study 2019.
    Lancet Infect Dis. 2021 Sep 23. pii: S1473-3099(21)00449.
    PubMed     Abstract available

  28. KIANG MV, Chin ET, Huynh BQ, Chapman LAC, et al
    Addendum needed on COVID-19 travel study - Authors' reply.
    Lancet Infect Dis. 2021 Sep 15. pii: S1473-3099(21)00562.

  29. HO CS, Feng PI, Narita M, Stout JE, et al
    Comparison of three tests for latent tuberculosis infection in high-risk people in the USA: an observational cohort study.
    Lancet Infect Dis. 2021 Sep 6. pii: S1473-3099(21)00145.
    PubMed     Abstract available

  30. KIRBY T
    Marta Lado-Ebola, HIV, sexual health and more.
    Lancet Infect Dis. 2021;21:1224.

    August 2021
  31. DAMHORST GL, Watts A, Hernandez-Romieu A, Mel N, et al
    Acanthamoeba castellanii encephalitis in a patient with AIDS: a case report and literature review.
    Lancet Infect Dis. 2021 Aug 27. pii: S1473-3099(20)30933.
    PubMed     Abstract available

  32. BURKI T
    Infected blood inquiry in the UK.
    Lancet Infect Dis. 2021;21:1078-1079.

    July 2021
    Uganda's Sexual Offences Bill-a step backwards.
    Lancet Infect Dis. 2021;21:920.

    June 2021
  34. KENYON G
    Hong Shang-leading HIV/AIDS research in China.
    Lancet Infect Dis. 2021;21:779.

  35. BURKI T
    HIV in the age of COVID-19.
    Lancet Infect Dis. 2021;21:774-775.

  36. VASAN S, Pitisuttithum P
    Vaccine development lessons between HIV and COVID-19.
    Lancet Infect Dis. 2021;21:759-761.

  37. KIRBY T
    Mario Poljak - Central Europe's pioneer in diagnostics.
    Lancet Infect Dis. 2021;21:780.

    Linda-Gail Bekker-a leader at the service of the world.
    Lancet Infect Dis. 2021;21:778.

  39. KAZI F, Mushtaq A
    Loretta Sweet Jemmott-a voice for the voiceless.
    Lancet Infect Dis. 2021;21:777.

    May 2021
  40. ARORA U, Garg P, Agarwal S, Nischal N, et al
    Complexities in the treatment of coinfection with HIV, hepatitis B, hepatitis C, and tuberculosis.
    Lancet Infect Dis. 2021 May 20. pii: S1473-3099(20)30765.
    PubMed     Abstract available

  41. DAL-RE R, Bekker LG, Gluud C, Holm S, et al
    Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities.
    Lancet Infect Dis. 2021 May 18. pii: S1473-3099(21)00263.
    PubMed     Abstract available

  42. CHALMERS RM, Alexander C
    Defining the diagnosis of cryptosporidiosis.
    Lancet Infect Dis. 2021;21:589-590.

  43. KAZI F, Mushtaq A
    CROI 2021.
    Lancet Infect Dis. 2021;21:606.

    April 2021
  44. CHAPPELL KJ, Mordant FL, Li Z, Wijesundara DK, et al
    Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Lancet Infect Dis. 2021 Apr 19. pii: S1473-3099(21)00200.
    PubMed     Abstract available

  45. STOTT KE, Loyse A, Jarvis JN, Alufandika M, et al
    Cryptococcal meningoencephalitis: time for action.
    Lancet Infect Dis. 2021 Apr 16. pii: S1473-3099(20)30771.
    PubMed     Abstract available

  46. SPINELLI MA, Rutherford G, Gandhi M
    Lowering SARS-CoV-2 viral load might affect transmission but not disease severity in secondary cases - Authors' reply.
    Lancet Infect Dis. 2021 Apr 14. pii: S1473-3099(21)00210.

    March 2021
  47. EL HALABI J, Palmer N, McDuffie M, Golub JJ, et al
    Measuring health-care delays among privately insured patients with tuberculosis in the USA: an observational cohort study.
    Lancet Infect Dis. 2021 Mar 23. pii: S1473-3099(20)30732.
    PubMed     Abstract available

  48. KIANG MV, Chin ET, Huynh BQ, Chapman LAC, et al
    Routine asymptomatic testing strategies for airline travel during the COVID-19 pandemic: a simulation study.
    Lancet Infect Dis. 2021 Mar 22. pii: S1473-3099(21)00134.
    PubMed     Abstract available

  49. GUILAMO-RAMOS V, Thimm-Kaiser M, Benzekri A, Hidalgo A, et al
    Nurses at the frontline of public health emergency preparedness and response: lessons learned from the HIV/AIDS pandemic and emerging infectious disease outbreaks.
    Lancet Infect Dis. 2021 Mar 18. pii: S1473-3099(20)30983.
    PubMed     Abstract available

  50. VAN DIJCK C, Tsoumanis A, Rotsaert A, Vuylsteke B, et al
    Antibacterial mouthwash to prevent sexually transmitted infections in men who have sex with men taking HIV pre-exposure prophylaxis (PReGo): a randomised, placebo-controlled, crossover trial.
    Lancet Infect Dis. 2021 Mar 4. pii: S1473-3099(20)30778.
    PubMed     Abstract available

  51. POZNIAK A, Meintjes G
    Raltegravir in patients with tuberculosis.
    Lancet Infect Dis. 2021 Mar 2. pii: S1473-3099(20)30937.

  52. DE CASTRO N, Marcy O, Chazallon C, Messou E, et al
    Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial.
    Lancet Infect Dis. 2021 Mar 2. pii: S1473-3099(20)30869.
    PubMed     Abstract available

    February 2021
  53. DODD PJ, Yuen CM, Jayasooriya SM, van der Zalm MM, et al
    Quantifying the global number of tuberculosis survivors: a modelling study.
    Lancet Infect Dis. 2021 Feb 25. pii: S1473-3099(20)30919.
    PubMed     Abstract available

  54. SPINELLI MA, Glidden DV, Gennatas ED, Bielecki M, et al
    Importance of non-pharmaceutical interventions in lowering the viral inoculum to reduce susceptibility to infection by SARS-CoV-2 and potentially disease severity.
    Lancet Infect Dis. 2021 Feb 22. pii: S1473-3099(20)30982.
    PubMed     Abstract available

  55. PRENTICE S, Nassanga B, Webb EL, Akello F, et al
    BCG-induced non-specific effects on heterologous infectious disease in Ugandan neonates: an investigator-blind randomised controlled trial.
    Lancet Infect Dis. 2021 Feb 17. pii: S1473-3099(20)30653.
    PubMed     Abstract available

  56. INZAULE SC, Tessema SK, Kebede Y, Ogwell Ouma AE, et al
    Genomic-informed pathogen surveillance in Africa: opportunities and challenges.
    Lancet Infect Dis. 2021 Feb 12. pii: S1473-3099(20)30939.
    PubMed     Abstract available

  57. DOOLEY KE, Rosenkranz SL, Conradie F, Moran L, et al
    QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
    Lancet Infect Dis. 2021 Feb 12. pii: S1473-3099(20)30770.
    PubMed     Abstract available

  58. MAKONI M
    New tuberculosis tests and drugs remain out of reach.
    Lancet Infect Dis. 2021;21:174.

    January 2021
  59. SCRIBA TJ, Fiore-Gartland A, Penn-Nicholson A, Mulenga H, et al
    Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial.
    Lancet Infect Dis. 2021 Jan 25. pii: S1473-3099(20)30914.
    PubMed     Abstract available

    December 2020
  60. HENGEL B, Causer L, Matthews S, Smith K, et al
    A decentralised point-of-care testing model to address inequities in the COVID-19 response.
    Lancet Infect Dis. 2020 Dec 23. pii: S1473-3099(20)30859.
    PubMed     Abstract available

  61. SAMER C, Lacombe K, Calmy A
    Cyber harassment of female scientists will not be the new norm.
    Lancet Infect Dis. 2020 Dec 23. pii: S1473-3099(20)30944.

  62. POUSTCHI H, Darvishian M, Mohammadi Z, Shayanrad A, et al
    SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.
    Lancet Infect Dis. 2020 Dec 15. pii: S1473-3099(20)30858.
    PubMed     Abstract available

  63. NKEREUWEM E, Togun T, Gomez MP, Szekely R, et al
    Comparing accuracy of lipoarabinomannan urine tests for diagnosis of pulmonary tuberculosis in children from four African countries: a cross-sectional study.
    Lancet Infect Dis. 2020 Dec 11. pii: S1473-3099(20)30598.
    PubMed     Abstract available

  64. HAMADA Y, Gupta RK, Matteelli A, Abubakar I, et al
    Predictive performance of interferon-gamma release assays and tuberculin skin tests.
    Lancet Infect Dis. 2020;20:1371-1372.

    November 2020
  65. KAZI F, Mushtaq A
    Primary care of patients with HIV.
    Lancet Infect Dis. 2020 Nov 27. pii: S1473-3099(20)30925.

  66. SHROUFI A, Chiller T, Jordan A, Denning DW, et al
    Ending deaths from HIV-related cryptococcal meningitis by 2030.
    Lancet Infect Dis. 2020 Nov 27. pii: S1473-3099(20)30909.

  67. KENYON C, Manoharan-Basil SS
    Macrolide consumption and resistance in Mycoplasma genitalium.
    Lancet Infect Dis. 2020;20:1235-1236.

    October 2020
  68. ETARD JF
    Immunity to Ebola virus: the full picture is being revealed.
    Lancet Infect Dis. 2020 Oct 13. pii: S1473-3099(20)30793.

  69. KIRBY T
    Evelina Tacconelli-two viruses, two wars.
    Lancet Infect Dis. 2020;20:1132.

    September 2020
  70. HIRONS A, Khoury G, Purcell DFJ
    Human T-cell lymphotropic virus type-1: a lifelong persistent infection, yet never truly silent.
    Lancet Infect Dis. 2020 Sep 25. pii: S1473-3099(20)30328.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO HIV Infection is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.